New medicines face big price cuts in Germany

Home/Policies & Legislation | Posted 14/01/2011 post-comment0 Post your comment

The pharmaceutical industry in Germany is facing price cuts expected to cost the industry more than Euros 2 billion per year, where parliament is set to approve the first price controls on newly approved innovator medicines. The law gives drugmakers one year to agree a price with insurers after new drugs are introduced, but if an agreement is not reached, the German Health Ministry will set maximum pricing and the product will undergo a cost-benefit analysis.


The abolition of free-pricing in Germany, the world’s third-biggest drug market after the US and Japan, is part of the austerity measures drawn up by the Health Minister with the aim of saving around Euros 2 billion during 2011.

The development is significant because many other countries use German prices in their reference pricing system. The bill follows temporary rebates and price freezes on drugs that the government imposed last summer to mitigate a huge deficit in the public insurance system that is forecast for next year.

Drug spending by the statutory sickness funds, which insure more than 70% of the German population, rose 5.3% last year as drugmakers increased prices of patent-protected medicines by 8.9%, according to the Health Ministry.

Generic prices, on the other hand, many of which are already fixed through mandatory discount contracts, fell by 2%. The law will only apply to drugs that are not yet on the market in Germany, and orphan drugs will be completely excluded.

The bill has only been approved so far by Germany’s lower house of parliament, or Bundestag. It will now have to pass the upper house of parliament, or Bundesrat, which is scheduled to take a vote on the issue on 26 November 2010, if approved the law would come into force on 1 January 2011.

Source: Bloomberg

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010